Focus on: Tirzepatide (Mounjaro) for weight management in General Practice 

We are pleased to announce that Shaba, Chair of Avon LMC, has written the guidance with the hat of BMA’s role. It has been published on BMA website.

From 23 June 2025, Tirzepatide must be implemented in primary care. Tirzepatide represents a new therapy for weight management, but requires structured implementation, appropriate monitoring, and clarity around responsibilities. GPs should engage in prescribing where clinically appropriate and safely resourced to do so.

GPC England has produced a Focus on Tirzepatide (Mounjaro) for weight management in General Practice document, which explains how Tirzepatide is used, commissioning arrangements (responsibility for funding lies with ICBs), and responding to information requests from private providers. 

The guidance also includes a template letter for practices to respond to requests for medical information following a private consultation.

Download full guidance here